Klinikai tapasztalatok levetiracetamkezeléssel felnottkori epilepsziákban.

Translated title of the contribution: Clinical experience with levetiracetam for adults with epilepsy

Gábor Barcs, A. Szűcs

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

OBJECTIVE: A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy. METHOD: Retrospective work up of our treatment-experiences with 55 pharmacoresistant patients treated with levetiracetam (11 of them on monotherapy) for 6-39 months. Three treatment groups were analysed: idiopathic generalised epilepsy (9 patients); partial epilepsy (30 patients); malignant or malignated epileptic syndromes (16 patients). RESULT: Seven idiopathic generalised patients (77%) and 5 partial epilepsy patients (16%) became seizure free. One idiopathic generalised epileptic patient, 10 partial epilepsy patients (33%) significantly improved. Six patients (37%) from the group of malignant or malignated epileptic syndromes also significantly improved. Five of the improved idiopathic generalised epilepsy patients and 6 of the improved partial epilepsy patients received levetiracetam monotherapy. Altogether seven patients (12% of the whole population) relapsed after a 4-15 months improved period. Fifteen patients (27%) suffered side effects (mainly somnolence, headache, dizziness and irritability) improving after dose reduction of levetiracetam (generally below 2000 mg pro day). CONCLUSION: Levetiracetam is an effective, well tolerable, broad-spectrum drug as adjunctive treatment or monotherapy in adult patients unsuccessfully treated with other antiepileptic drugs.

Original languageHungarian
Pages (from-to)31-34
Number of pages4
JournalIdeggyógyászati szemle
Volume60
Issue number1-2
Publication statusPublished - Jan 20 2007

Fingerprint

etiracetam
Epilepsy
Partial Epilepsy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Klinikai tapasztalatok levetiracetamkezeléssel felnottkori epilepsziákban. / Barcs, Gábor; Szűcs, A.

In: Ideggyógyászati szemle, Vol. 60, No. 1-2, 20.01.2007, p. 31-34.

Research output: Contribution to journalArticle

@article{1466fa2155dc4f87bf2e0a82f5ec68c5,
title = "Klinikai tapasztalatok levetiracetamkezel{\'e}ssel felnottkori epilepszi{\'a}kban.",
abstract = "OBJECTIVE: A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy. METHOD: Retrospective work up of our treatment-experiences with 55 pharmacoresistant patients treated with levetiracetam (11 of them on monotherapy) for 6-39 months. Three treatment groups were analysed: idiopathic generalised epilepsy (9 patients); partial epilepsy (30 patients); malignant or malignated epileptic syndromes (16 patients). RESULT: Seven idiopathic generalised patients (77{\%}) and 5 partial epilepsy patients (16{\%}) became seizure free. One idiopathic generalised epileptic patient, 10 partial epilepsy patients (33{\%}) significantly improved. Six patients (37{\%}) from the group of malignant or malignated epileptic syndromes also significantly improved. Five of the improved idiopathic generalised epilepsy patients and 6 of the improved partial epilepsy patients received levetiracetam monotherapy. Altogether seven patients (12{\%} of the whole population) relapsed after a 4-15 months improved period. Fifteen patients (27{\%}) suffered side effects (mainly somnolence, headache, dizziness and irritability) improving after dose reduction of levetiracetam (generally below 2000 mg pro day). CONCLUSION: Levetiracetam is an effective, well tolerable, broad-spectrum drug as adjunctive treatment or monotherapy in adult patients unsuccessfully treated with other antiepileptic drugs.",
author = "G{\'a}bor Barcs and A. Szűcs",
year = "2007",
month = "1",
day = "20",
language = "Hungarian",
volume = "60",
pages = "31--34",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "1-2",

}

TY - JOUR

T1 - Klinikai tapasztalatok levetiracetamkezeléssel felnottkori epilepsziákban.

AU - Barcs, Gábor

AU - Szűcs, A.

PY - 2007/1/20

Y1 - 2007/1/20

N2 - OBJECTIVE: A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy. METHOD: Retrospective work up of our treatment-experiences with 55 pharmacoresistant patients treated with levetiracetam (11 of them on monotherapy) for 6-39 months. Three treatment groups were analysed: idiopathic generalised epilepsy (9 patients); partial epilepsy (30 patients); malignant or malignated epileptic syndromes (16 patients). RESULT: Seven idiopathic generalised patients (77%) and 5 partial epilepsy patients (16%) became seizure free. One idiopathic generalised epileptic patient, 10 partial epilepsy patients (33%) significantly improved. Six patients (37%) from the group of malignant or malignated epileptic syndromes also significantly improved. Five of the improved idiopathic generalised epilepsy patients and 6 of the improved partial epilepsy patients received levetiracetam monotherapy. Altogether seven patients (12% of the whole population) relapsed after a 4-15 months improved period. Fifteen patients (27%) suffered side effects (mainly somnolence, headache, dizziness and irritability) improving after dose reduction of levetiracetam (generally below 2000 mg pro day). CONCLUSION: Levetiracetam is an effective, well tolerable, broad-spectrum drug as adjunctive treatment or monotherapy in adult patients unsuccessfully treated with other antiepileptic drugs.

AB - OBJECTIVE: A retrospective study to evaluate the efficacy of levetiracetam in the treatment of adult pharmacoresistant epilepsy. METHOD: Retrospective work up of our treatment-experiences with 55 pharmacoresistant patients treated with levetiracetam (11 of them on monotherapy) for 6-39 months. Three treatment groups were analysed: idiopathic generalised epilepsy (9 patients); partial epilepsy (30 patients); malignant or malignated epileptic syndromes (16 patients). RESULT: Seven idiopathic generalised patients (77%) and 5 partial epilepsy patients (16%) became seizure free. One idiopathic generalised epileptic patient, 10 partial epilepsy patients (33%) significantly improved. Six patients (37%) from the group of malignant or malignated epileptic syndromes also significantly improved. Five of the improved idiopathic generalised epilepsy patients and 6 of the improved partial epilepsy patients received levetiracetam monotherapy. Altogether seven patients (12% of the whole population) relapsed after a 4-15 months improved period. Fifteen patients (27%) suffered side effects (mainly somnolence, headache, dizziness and irritability) improving after dose reduction of levetiracetam (generally below 2000 mg pro day). CONCLUSION: Levetiracetam is an effective, well tolerable, broad-spectrum drug as adjunctive treatment or monotherapy in adult patients unsuccessfully treated with other antiepileptic drugs.

UR - http://www.scopus.com/inward/record.url?scp=34250200131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250200131&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 31

EP - 34

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 1-2

ER -